{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:51:41Z","timestamp":1782971501697,"version":"3.54.5"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mammary Gland Biol Neoplasia"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The isogenic, tumor-bearing Dark Agouti Mammary Adenocarcinoma (DAMA) model is commonly utilized in breast cancer research to evaluate mechanisms of, and interventions for chemotherapy-induced toxicity and tumor response. However, the biological subtype, immune landscape, and genomic profile of DAMA have remained uncharacterized. In this study, we comprehensively evaluated DAMA tumors na\u00efve and exposed to methotrexate, assessing their histopathological, molecular, and genomic features. Our findings reveal that the DAMA model presents a platform to model the human triple-negative breast cancer (TNBC), as it exhibits substantial macrophage infiltration, the tumors display dysregulation of oncogenes\n                    <jats:italic>Bcl2<\/jats:italic>\n                    ,\n                    <jats:italic>Egfr<\/jats:italic>\n                    , and potentially\n                    <jats:italic>Myc<\/jats:italic>\n                    , suggesting apoptotic resistance as a key mechanism driving growth. These characteristics position the DAMA model as a potential preclinical model for investigating TNBC biology, therapeutic responses, and drug toxicity.\n                  <\/jats:p>","DOI":"10.1007\/s10911-026-09606-x","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:16:04Z","timestamp":1775808964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Molecular and Genomic Landscape of the Dark Agouti Rat Mammary Adenocarcinoma: Preliminary Insights for Triple-Negative Breast Cancer Modeling"],"prefix":"10.1007","volume":"31","author":[{"given":"Ifeoma J.","family":"Dikeocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah R.","family":"Wardill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"6","key":"9606_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.5858\/arpa.2017-0169-OA","volume":"142","author":"S Kizy","year":"2018","unstructured":"Kizy S, et al. Distribution of 21-Gene Recurrence Scores among Breast Cancer Histologic Subtypes. Arch Pathol Lab Med. 2018;142(6):735\u201341.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"9606_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1634\/theoncologist.2017-0535","volume":"23","author":"JJ Gao","year":"2018","unstructured":"Gao JJ, Swain SM. Luminal a Breast Cancer and Molecular Assays: A Review. Oncologist. 2018;23(5):556\u201365.","journal-title":"Oncologist"},{"issue":"25","key":"9606_CR3","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","volume":"32","author":"F Ades","year":"2014","unstructured":"Ades F, et al. Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. J Clin Oncol. 2014;32(25):2794\u2013803.","journal-title":"J Clin Oncol"},{"key":"9606_CR4","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.ctrv.2020.101965","volume":"84","author":"F Schettini","year":"2020","unstructured":"Schettini F, et al. HER2-Enriched Subtype and Pathological Complete Response in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. Cancer Treat Rev. 2020;84:101965.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"9606_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","volume":"27","author":"FM Howard","year":"2021","unstructured":"Howard FM, Olopade OI. Epidemiology of Triple-Negative Breast Cancer: A Review. Cancer J. 2021;27(1):8\u201316.","journal-title":"Cancer J"},{"issue":"6","key":"9606_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1365-2559.2011.03912.x","volume":"60","author":"HO Habashy","year":"2012","unstructured":"Habashy HO, et al. A Review of the Biological and Clinical Characteristics of Luminal-Like Oestrogen Receptor\u2010Positive Breast Cancer. Histopathology. 2012;60(6):854\u201363.","journal-title":"Histopathology"},{"key":"9606_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/B978-0-12-415894-8.00040-3","volume-title":"Animal Models for the Study of Human Disease","author":"J Welsh","year":"2013","unstructured":"Welsh J. Chap. 40 - Animal Models for Studying Prevention and Treatment of Breast Cancer. Animal Models for the Study of Human Disease. Boston: Academic; P.M. Conn, Editor. 2013. p. 997\u20131018."},{"key":"9606_CR8","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1023\/A:1021061306913","volume":"47","author":"RJ Gibson","year":"2002","unstructured":"Gibson RJ, et al. Effect of Interleukin-11 on Ameliorating Intestinal Damage After Methotrexate Treatment of Breast Cancer in Rats. Dig Dis Sci. 2002;47:2751\u20137.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"9606_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1046\/j.1440-1746.2003.03136.x","volume":"18","author":"RJ Gibson","year":"2003","unstructured":"Gibson RJ, et al. Irinotecan Causes Severe Small Intestinal Damage, as well as Colonic Damage, in the Rat with Implanted Breast Cancer. J Gastroenterol Hepatol. 2003;18(9):1095\u2013100.","journal-title":"J Gastroenterol Hepatol"},{"key":"9606_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00280-006-0275-9","volume":"59","author":"JM Bowen","year":"2007","unstructured":"Bowen JM, et al. Irinotecan Changes Gene Expression in the Small Intestine of the Rat with Breast Cancer. Cancer Chemother Pharmacol. 2007;59:337\u201348.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"9606_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1177\/1535370213493718","volume":"238","author":"S Mashtoub","year":"2013","unstructured":"Mashtoub S, Tran CD, Howarth GS. Emu Oil Expedites Small Intestinal Repair Following 5-Fluorouracil-Induced Mucositis in Rats. Experimental Biology Med. 2013;238(11):1305\u201317.","journal-title":"Experimental Biology Med"},{"issue":"2","key":"9606_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4161\/cbt.27222","volume":"15","author":"HR Wardill","year":"2014","unstructured":"Wardill HR, et al. Irinotecan Disrupts Tight Junction Proteins Within the Gut: Implications for Chemotherapy-Induced Gut Toxicity. Cancer Biol Ther. 2014;15(2):236\u201344.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"9606_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1042\/bj3010769","volume":"301","author":"FM Tomas","year":"1994","unstructured":"Tomas FM, et al. Effects of Insulin and insulin-Like Growth Factors on Protein and Energy Metabolism in Tumour-Bearing Rats. Biochem J. 1994;301(3):769\u201375.","journal-title":"Biochem J"},{"issue":"10","key":"9606_CR14","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.3390\/nu5103948","volume":"5","author":"E Bateman","year":"2013","unstructured":"Bateman E, et al. Investigation of Effect of Nutritional Drink on Chemotherapy-Induced Mucosal Injury and Tumor Growth in an Established Animal Model. Nutrients. 2013;5(10):3948\u201363.","journal-title":"Nutrients"},{"issue":"2","key":"9606_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4161\/cbt.12.2.15720","volume":"12","author":"KL Tooley","year":"2011","unstructured":"Tooley KL, et al. Oral Ingestion of Streptococcus Thermophilus Does not Affect Mucositis Severity or Tumor Progression in the Tumor-Bearing Rat. Cancer Biol Ther. 2011;12(2):131\u20138.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"9606_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41419-023-05850-9","volume":"14","author":"HR Wardill","year":"2023","unstructured":"Wardill HR, et al. Whey-based diet containing medium chain triglycerides modulates the gut microbiota and protects the intestinal mucosa from chemotherapy while maintaining therapy efficacy. Cell Death Dis. 2023;14(5):338.","journal-title":"Cell Death Dis"},{"issue":"9","key":"9606_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/ncponc0908","volume":"4","author":"AH Sims","year":"2007","unstructured":"Sims AH, et al. Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol. 2007;4(9):516\u201325.","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"9606_CR18","first-page":"18","volume":"8","author":"U Testa","year":"2020","unstructured":"Testa U, Castelli G, Pelosi E. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. Med Sci. 2020;8(1):18.","journal-title":"Med Sci"},{"issue":"3","key":"9606_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5(3):412.","journal-title":"World J Clin Oncol"},{"issue":"6","key":"9606_CR20","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1177\/1535370215581309","volume":"240","author":"B Vanhoecke","year":"2015","unstructured":"Vanhoecke B, et al. Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. Experimental Biology Med. 2015;240(6):725\u201341.","journal-title":"Experimental Biology Med"},{"issue":"16","key":"9606_CR21","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"MEH Hammond","year":"2010","unstructured":"Hammond MEH, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784\u201395.","journal-title":"J Clin Oncol"},{"issue":"10","key":"9606_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNCI: J Natl Cancer Inst. 2009;101(10):736\u201350.","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"1","key":"9606_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2006","unstructured":"Wolff AC, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006;25(1):118\u201345.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9606_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.breast.2011.07.008","volume":"21","author":"S Park","year":"2012","unstructured":"Park S, et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast. 2012;21(1):50\u20137.","journal-title":"Breast"},{"issue":"9","key":"9606_CR25","doi-asserted-by":"publisher","first-page":"8415","DOI":"10.18632\/oncotarget.23865","volume":"9","author":"B H\u00f6ing","year":"2018","unstructured":"H\u00f6ing B, et al. Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma. Oncotarget. 2018;9(9):8415\u201326.","journal-title":"Oncotarget"},{"issue":"1","key":"9606_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17(1):122.","journal-title":"Genome Biol"},{"issue":"1","key":"9606_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Stat Soc: Ser B (Methodol). 1995;57(1):289\u2013300.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"issue":"2","key":"9606_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.25122\/jml-2021-0108","volume":"15","author":"A Baranova","year":"2022","unstructured":"Baranova A, et al. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis. J Med Life. 2022;15(2):153.","journal-title":"J Med Life"},{"key":"9606_CR29","doi-asserted-by":"publisher","first-page":"769280","DOI":"10.3389\/fonc.2021.769280","volume":"11","author":"G Barchiesi","year":"2021","unstructured":"Barchiesi G, et al. Emerging role of PARP inhibitors in metastatic triple negative breast cancer. Current scenario and future perspectives. Front Oncol. 2021;11:769280.","journal-title":"Front Oncol"},{"issue":"7","key":"9606_CR30","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15(7):1796.","journal-title":"Pharmaceutics"},{"issue":"1","key":"9606_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21873\/anticanres.16137","volume":"43","author":"NB Katuwal","year":"2023","unstructured":"Katuwal NB, et al. Preclinical platform using a triple-negative breast cancer syngeneic murine model to evaluate immune checkpoint inhibitors. Anticancer Res. 2023;43(1):85\u201395.","journal-title":"Anticancer Res"},{"key":"9606_CR32","doi-asserted-by":"publisher","unstructured":"Bu W, Li Y. Rat Models of Breast Cancer. A Guide to Breast Cancer Research: From Cellular Heterogeneity and Molecular Mechanisms to Therapy. 2025;1464:123\u201348. https:\/\/doi.org\/10.1007\/978-3-031-70875-6_8.","DOI":"10.1007\/978-3-031-70875-6_8"},{"key":"9606_CR33","doi-asserted-by":"crossref","unstructured":"Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manage Res, 2022: pp. 1\u201317.","DOI":"10.2147\/CMAR.S316700"},{"issue":"12","key":"9606_CR34","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1158\/1055-9965.EPI-19-0469","volume":"28","author":"L Deng","year":"2019","unstructured":"Deng L, et al. Immune Profiles of Tumor Microenvironment and Clinical Prognosis Among Women with Triple-Negative Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(12):1977\u201385.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9606_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fcell.2020.00162","volume":"8","author":"V Vafaizadeh","year":"2020","unstructured":"Vafaizadeh V, Barekati Z. Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer. Front cell Dev biology. 2020;8:162.","journal-title":"Front cell Dev biology"},{"issue":"7","key":"9606_CR36","first-page":"452","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL. Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations. Pharm Ther. 2017;42(7):452.","journal-title":"Pharm Ther"},{"issue":"7","key":"9606_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.drudis.2021.03.011","volume":"26","author":"S Singh","year":"2021","unstructured":"Singh S, et al. The Emerging Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer. Drug Discovery Today. 2021;26(7):1721\u20137.","journal-title":"Drug Discovery Today"},{"issue":"1","key":"9606_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/me.2009-0252","volume":"24","author":"TH Charn","year":"2010","unstructured":"Charn TH, et al. Genome-Wide Dynamics of Chromatin Binding of Estrogen Receptors \u03b1 and \u03b2: Mutual Restriction and Competitive Site Selection. Mol Endocrinol. 2010;24(1):47\u201359.","journal-title":"Mol Endocrinol"},{"issue":"1","key":"9606_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12282-012-0354-1","volume":"21","author":"H Nakajima","year":"2014","unstructured":"Nakajima H, et al. Protein Expression, Gene Amplification, and Mutational Analysis of EGFR in Triple-Negative Breast Cancer. Breast Cancer. 2014;21(1):66\u201374.","journal-title":"Breast Cancer"},{"issue":"9","key":"9606_CR40","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","volume":"27","author":"HS Park","year":"2014","unstructured":"Park HS, et al. High EGFR Gene Copy Number Predicts Poor Outcome in Triple-Negative Breast Cancer. Mod Pathol. 2014;27(9):1212\u201322.","journal-title":"Mod Pathol"},{"issue":"3","key":"9606_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/annonc\/mdm509","volume":"19","author":"M Colleoni","year":"2008","unstructured":"Colleoni M, et al. Expression of ER, PgR, HER1, HER2, and Response: A Study of Preoperative Chemotherapy. Ann Oncol. 2008;19(3):465\u201372.","journal-title":"Ann Oncol"},{"issue":"11","key":"9606_CR42","first-page":"1233","volume":"22","author":"C Anders","year":"2008","unstructured":"Anders C, Carey LA. Understanding and Treating Triple-Negative Breast Cancer. Oncol (Williston Park). 2008;22(11):1233\u20139. discussion 1239-40, 1243.","journal-title":"Oncol (Williston Park)"},{"key":"9606_CR43","doi-asserted-by":"crossref","unstructured":"Ma J et al. Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins. Breast Cancer: Targets Therapy. 2023: p. 11\u201324.","DOI":"10.2147\/BCTT.S390017"},{"key":"9606_CR44","doi-asserted-by":"publisher","unstructured":"Xiong N, Wu H, Yu Z. Advancements and Challenges in Triple-Negative Breast Cancer: A Comprehensive Review of Therapeutic and Diagnostic Strategies. Front Oncol. 2024;14:1\u201310. https:\/\/doi.org\/10.3389\/fonc.2024.1405491.","DOI":"10.3389\/fonc.2024.1405491"},{"issue":"6","key":"9606_CR45","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2967\/jnumed.112.111534","volume":"54","author":"F Al-Ejeh","year":"2013","unstructured":"Al-Ejeh F, et al. Treatment of Triple-Negative Breast Cancer Using Anti-EGFR\u2013Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor. J Nucl Med. 2013;54(6):913\u201321.","journal-title":"J Nucl Med"},{"issue":"13","key":"9606_CR46","first-page":"6632","volume":"11","author":"X Liu","year":"2021","unstructured":"Liu X, et al. EGFR Inhib Blocks Cancer Stem Cell Clustering Lung Metastasis Triple Negat Breast Cancer Theranostics. 2021;11(13):6632\u201343.","journal-title":"EGFR Inhib Blocks Cancer Stem Cell Clustering Lung Metastasis Triple Negat Breast Cancer Theranostics"},{"issue":"8","key":"9606_CR47","first-page":"1609","volume":"6","author":"K Nakai","year":"2016","unstructured":"Nakai K, Hung M-C, Yamaguchi H. A perspective on Anti-EGFR Therapies Targeting Triple-Negative Breast Cancer. Am J cancer Res. 2016;6(8):1609.","journal-title":"Am J cancer Res"},{"issue":"4","key":"9606_CR48","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/1055-9965.EPI-05-0679","volume":"15","author":"KA Pooley","year":"2006","unstructured":"Pooley KA, et al. Association of the Progesterone Receptor Gene with Breast Cancer Risk: A Single-Nucleotide Polymorphism Tagging Approach. Cancer Epidemiol Biomarkers Prev. 2006;15(4):675\u201382.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9606_CR49","doi-asserted-by":"crossref","unstructured":"Vang A, Salem K, Fowler AM. Progesterone Receptor Gene Polymorphisms Breast Cancer Risk Endocrinol. 2023;164(4):1\u201316.","DOI":"10.1210\/endocr\/bqad020"},{"issue":"4","key":"9606_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1269\/jrr.07126","volume":"49","author":"T Imaoka","year":"2008","unstructured":"Imaoka T, et al. Gene Expression Profiling Distinguishes Between Spontaneous and Radiation-Induced Rat Mammary Carcinomas. J Radiat Res. 2008;49(4):349\u201360.","journal-title":"J Radiat Res"},{"issue":"1","key":"9606_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21873\/anticanres.14751","volume":"41","author":"H Moriyama","year":"2021","unstructured":"Moriyama H, et al. Exome of Radiation-Induced Rat Mammary Carcinoma Shows Copy-Number Losses and Mutations in Human-Relevant Cancer Genes. Anticancer Res. 2021;41(1):55\u201370.","journal-title":"Anticancer Res"},{"key":"9606_CR52","doi-asserted-by":"publisher","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","volume":"12","author":"S Qian","year":"2022","unstructured":"Qian S, et al. The Role of BCL-2 Family Proteins in Regulating Apoptosis and Cancer Therapy. Front Oncol. 2022;12:985363.","journal-title":"Front Oncol"},{"issue":"8","key":"9606_CR53","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1021\/acs.molpharmaceut.3c00009","volume":"20","author":"MA Scully","year":"2023","unstructured":"Scully MA, et al. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer. Mol Pharm. 2023;20(8):3895\u2013913.","journal-title":"Mol Pharm"},{"issue":"39","key":"9606_CR54","doi-asserted-by":"publisher","first-page":"25545","DOI":"10.18632\/oncotarget.25370","volume":"9","author":"T Inao","year":"2018","unstructured":"Inao T, et al. Bcl-2 Inhibition Sensitizes Triple-Negative Human Breast Cancer Cells to Doxorubicin. Oncotarget. 2018;9(39):25545.","journal-title":"Oncotarget"},{"issue":"3","key":"9606_CR55","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41388-019-1001-5","volume":"39","author":"N Kiavue","year":"2020","unstructured":"Kiavue N, et al. ERBB3 Mutations in Cancer: Biological Aspects, Prevalence and Therapeutics. Oncogene. 2020;39(3):487\u2013502.","journal-title":"Oncogene"},{"issue":"6","key":"9606_CR56","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/1947601910378691","volume":"1","author":"J Xu","year":"2010","unstructured":"Xu J, Chen Y, Olopade OI. MYC and Breast Cancer. Genes Cancer. 2010;1(6):629\u201340.","journal-title":"Genes Cancer"},{"issue":"1","key":"9606_CR57","doi-asserted-by":"publisher","first-page":"6579","DOI":"10.1038\/s41467-022-34000-6","volume":"13","author":"D Zimmerli","year":"2022","unstructured":"Zimmerli D, et al. MYC Promotes Immune-Suppression in Triple-Negative Breast Cancer Via Inhibition of Interferon Signaling. Nat Commun. 2022;13(1):6579.","journal-title":"Nat Commun"},{"issue":"1","key":"9606_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13205-024-04195-0","volume":"15","author":"A Priya","year":"2025","unstructured":"Priya A, Kumar, Kumar D. Molecular Heterogeneity and MYC Dysregulation in Triple-Negative Breast Cancer: Genomic Advances and Therapeutic Implications. 3 Biotech. 2025;15(1):33.","journal-title":"3 Biotech"},{"issue":"24","key":"9606_CR59","doi-asserted-by":"publisher","first-page":"9486","DOI":"10.3390\/ijms21249486","volume":"21","author":"J McAnulty","year":"2020","unstructured":"McAnulty J, DiFeo A. The Molecular \u2018Myc-anisms\u2019 behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics. Int J Mol Sci. 2020;21(24):9486.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9606_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12964-023-01043-1","volume":"21","author":"F-y Gao","year":"2023","unstructured":"Gao F-y, et al. c-MYC Mediates the Crosstalk Between Breast Cancer Cells and Tumor Microenvironment. Cell Communication Signal. 2023;21(1):28.","journal-title":"Cell Communication Signal"},{"issue":"11","key":"9606_CR61","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/nm.4213","volume":"22","author":"D Horiuchi","year":"2016","unstructured":"Horiuchi D, et al. PIM1 Kinase Inhibition as a Targeted Therapy Against Triple-Negative Breast Tumors with Elevated MYC Expression. Nat Med. 2016;22(11):1321\u20139.","journal-title":"Nat Med"},{"issue":"5\u20136","key":"9606_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.18632\/oncoscience.414","volume":"5","author":"N Klauber-DeMore","year":"2018","unstructured":"Klauber-DeMore N, Schulte BA, Wang GY. Targeting MYC for Triple-Negative Breast Cancer Treatment. Oncoscience. 2018;5(5\u20136):120\u20131.","journal-title":"Oncoscience"},{"issue":"2","key":"9606_CR63","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10549-022-06673-6","volume":"195","author":"M Tang","year":"2022","unstructured":"Tang M, et al. MYC as a Therapeutic Target for the Treatment of Triple-Negative Breast Cancer: Preclinical Investigations with the Novel MYC Inhibitor, MYCi975. Breast Cancer Res Treat. 2022;195(2):105\u201315.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"9606_CR64","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3390\/life11111247","volume":"11","author":"M Prvanovi\u0107","year":"2021","unstructured":"Prvanovi\u0107 M, et al. Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer. Life. 2021;11(11):1247.","journal-title":"Life"},{"issue":"6","key":"9606_CR65","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1158\/1078-0432.CCR-04-1633","volume":"11","author":"NL Barnes","year":"2005","unstructured":"Barnes NL, et al. Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma in Situ of the Breast. Clin Cancer Res. 2005;11(6):2163\u20138.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"9606_CR66","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80(14):2969\u201374.","journal-title":"Cancer Res"},{"key":"9606_CR67","doi-asserted-by":"crossref","unstructured":"Moon A. Ras Signaling in Breast Cancer. Translational Research in Breast Cancer. Springer Singapore: Singapore; D.-Y. Noh, W. Han, and M. Toi, Editors. 2021;1187:81\u2013101. https:\/\/link.springer.com\/chapter\/10.1007\/978-981-32-9620-6_4.","DOI":"10.1007\/978-981-32-9620-6_4"},{"issue":"1","key":"9606_CR68","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-024-01631-9","volume":"17","author":"X Yang","year":"2024","unstructured":"Yang X, Wu H. RAS Signaling in Carcinogenesis, Cancer Therapy and Resistance Mechanisms. J Hematol Oncol. 2024;17(1):108.","journal-title":"J Hematol Oncol"},{"key":"9606_CR69","doi-asserted-by":"publisher","unstructured":"Mohanty SS, Sahoo CR, Padhy RN. Role of Hormone Receptors and HER2 as Prospective Molecular Markers for Breast Cancer: An update. Genes & diseases. 2022;9(3):648\u201358. https:\/\/doi.org\/10.1016\/j.gendis.2020.12.005.","DOI":"10.1016\/j.gendis.2020.12.005"},{"issue":"10","key":"9606_CR70","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2478\/v10035-011-0087-4","volume":"83","author":"P Pluta","year":"2011","unstructured":"Pluta P, et al. Significance of Bax Expression in Breast Cancer Patients. Polski przeglad chirurgiczny. 2011;83(10):549\u201353.","journal-title":"Polski przeglad chirurgiczny"},{"issue":"4","key":"9606_CR71","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tcb.2020.12.011","volume":"31","author":"AM Boutelle","year":"2021","unstructured":"Boutelle AM, Attardi LD. 53 and Tumor Suppression: It Takes a Network. Trends Cell Biol. 2021;31(4):298\u2013310.","journal-title":"Trends Cell Biol"},{"issue":"12","key":"9606_CR72","doi-asserted-by":"publisher","first-page":"e0142466","DOI":"10.1371\/journal.pone.0142466","volume":"10","author":"S-H Tan","year":"2015","unstructured":"Tan S-H, et al. High-Throughput Mutation Profiling Changes Before and 3 Weeks After Chemotherapy in Newly Diagnosed Breast Cancer Patients. PLoS ONE. 2015;10(12):e0142466.","journal-title":"PLoS ONE"},{"issue":"1 suppl 1","key":"9606_CR73","doi-asserted-by":"publisher","first-page":"e20190138","DOI":"10.1590\/1678-4685-gmb-2019-0138","volume":"43","author":"LM Primo","year":"2019","unstructured":"Primo LM, Teixeira LK. DNA Replication Stress: Oncogenes in the Spotlight. Genet Mol biology. 2019;43(1 suppl 1):e20190138.","journal-title":"Genet Mol biology"},{"issue":"1","key":"9606_CR74","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13058-025-01969-z","volume":"27","author":"G Schmidt","year":"2025","unstructured":"Schmidt G, et al. HER2-Low Status as a Distinct Breast Cancer Subtype: Myth or Truth? Analysis of the WSG Trials WSG-ADAPT-HR+\/HER2-, WSG-PlanB, and WSG-ADAPT-TN. Breast Cancer Res. 2025;27(1):22.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"9606_CR75","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.3390\/ijms25021318","volume":"25","author":"Y-F Tsai","year":"2024","unstructured":"Tsai Y-F, et al. Genomic Alterations of Tumors in HER2-Low Breast Cancers. Int J Mol Sci. 2024;25(2):1318.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"9606_CR76","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","volume":"20","author":"A Moyer","year":"2025","unstructured":"Moyer A, Tanaka K, Cheng EH. Apoptosis in Cancer Biology and Therapy. Annu Rev Pathol. 2025;20(1):303\u201328.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"9606_CR77","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","volume":"17","author":"Y Shi","year":"2018","unstructured":"Shi Y, et al. Therapeutic landscape in Mutational Triple Negative Breast Cancer. Mol Cancer. 2018;17(1):99.","journal-title":"Mol Cancer"},{"key":"9606_CR78","doi-asserted-by":"publisher","unstructured":"Kim R et al. Whole-Genome Landscapes of 1,364 Breast Cancers. Nature. 2025;649:1282\u201391 . https:\/\/doi.org\/10.1038\/s41586-025-09812-3.","DOI":"10.1038\/s41586-025-09812-3"},{"key":"9606_CR79","doi-asserted-by":"crossref","unstructured":"Piemonte KM, Anstine LJ, Keri RA. Centrosome Aberrations as Drivers Chromosomal Instability Breast Cancer Endocrinol. 2021;162(12):1\u201314.","DOI":"10.1210\/endocr\/bqab208"},{"issue":"1","key":"9606_CR80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41698-021-00155-6","volume":"5","author":"IAEM van Belzen","year":"2021","unstructured":"van Belzen IAEM, et al. Structural Variant Detection in Cancer Genomes: Computational Challenges and Perspectives for Precision Oncology. npj Precision Oncol. 2021;5(1):15.","journal-title":"npj Precision Oncol"},{"issue":"1","key":"9606_CR81","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41467-019-11236-3","volume":"10","author":"JP Rennhack","year":"2019","unstructured":"Rennhack JP, et al. Integrated Analyses of Murine Breast Cancer Models Reveal Critical Parallels with Human Disease. Nat Commun. 2019;10(1):3261.","journal-title":"Nat Commun"},{"issue":"11","key":"9606_CR82","doi-asserted-by":"publisher","first-page":"e1003027","DOI":"10.1371\/journal.pgen.1003027","volume":"8","author":"P Kumar","year":"2012","unstructured":"Kumar P, et al. Cooperativity of Rb, Brca1, and p53 in Malignant Breast Cancer Evolution. PLoS Genet. 2012;8(11):e1003027.","journal-title":"PLoS Genet"},{"issue":"1","key":"9606_CR83","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-023-01723-3","volume":"25","author":"CD Broeker","year":"2023","unstructured":"Broeker CD, et al. Integrative Multi-Omic Sequencing Reveals the MMTV-Myc Mouse Model Mimics Human Breast Cancer Heterogeneity. Breast Cancer Res. 2023;25(1):120.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"9606_CR84","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-013-2798-1","volume":"143","author":"E Tilch","year":"2014","unstructured":"Tilch E, et al. Mutations in EGFR, BRAF and RAS are Rare in Triple-Negative and Basal-Like Breast Cancers from Caucasian Women. Breast Cancer Res Treat. 2014;143(2):385\u201392.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"9606_CR85","first-page":"357","volume":"49","author":"CF Rochlitz","year":"1989","unstructured":"Rochlitz CF, et al. Incidence of Activating Ras Oncogene Mutations Associated with Primary and Metastatic Human Breast Cancer. Cancer Res. 1989;49(2):357\u201360.","journal-title":"Cancer Res"}],"container-title":["Journal of Mammary Gland Biology and Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10911-026-09606-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10911-026-09606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10911-026-09606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:08:21Z","timestamp":1778580501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10911-026-09606-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["9606"],"URL":"https:\/\/doi.org\/10.1007\/s10911-026-09606-x","relation":{},"ISSN":["1083-3021","1573-7039"],"issn-type":[{"value":"1083-3021","type":"print"},{"value":"1573-7039","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15"}}